Endothelial effects of leptin: Implications in health and diseases

被引：45

作者：

Rahmouni K. ^{[1
]}

Haynes W.G. ^{[1
]}

机构：

[1] Department of Internal Medicine, General Clinical Research Center, University of Iowa College of Medicine, Iowa City, IA 52242

来源：

Current Diabetes Reports | 2005年 / 5卷 / 4期

关键词：

Nitric Oxide; Vascular Endothelial Growth Factor; Human Umbilical Vein Endothelial Cell; Vascular Endothelial Growth Factor mRNA; Vascular Endothelial Growth Factor Gene;

D O I：

10.1007/s11892-005-0020-5

中图分类号：

学科分类号：

摘要：

Leptin is an adipocyte-clerived hormone that plays a major role in the regulation of energy homeostasis through its action in the central nervous system. Leptin also acts on several peripheral tissues, including the vascular endothelium. The leptin receptor has been identified in endothelial cells. Leptin action on the endothelium modulates several physiologic processes, with potential implications in pathophysiologic diseases associated with obesity. Leptin stimulation of angiogenesis has attracted attention because of its potential involvement in retinopathy and atherosclerosis. Leptin activation of endothelial oxidative stress also has implications in atherosclerosis and inflammation. However, data on the impact of the endothelial effect of leptin on arterial pressure are contrasting. Although some investigators have shown that leptin action on the endothelial nitric oxide system tends to decrease arterial pressure, others have shown no contribution from the endothelial effect of leptin to the control of arterial pressure. Further characterization of the endothelial effects of leptin will, it is hoped, help in the understanding of the different pathophysiologic diseases associated with obesity. Copyright © 2005 by Current Science Inc.

引用

页码：260 / 266

页数：6

共 49 条

[1]

Friedman J.M., Halaas J.L., Leptin and the regulation of body weight in mammals, Nature, 395, pp. 763-770, (1998)

[2]

Banks W.A., Kastin A.J., Huang W., Et al., Leptin enters the brain by a saturable system independent of insulin, Peptides, 17, pp. 305-311, (1996)

[3]

Farooqi I.S., O'Rahilly S., Monogenic obesity in humans, Annu. Rev. Med., 56, pp. 443-458, (2005)

[4]

Haynes W.G., Morgan D.A., Walsh S.A., Et al., Receptor-mediated regional sympathetic nerve activation by leptin, J. Clin. Invest., 100, pp. 270-278, (1997)

[5]

Dunbar J.C., Hu Y., Lu H., Intracerebroventricular leptin increases lumbar and renal sympathetic nerve activity and blood pressure in normal rats, Diabetes, 46, pp. 2040-2043, (1997)

[6]

Sinha M.K., Opentanova I., Ohannesian J.P., Et al., Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting, J. Clin. Invest., 98, pp. 1277-1282, (1996)

[7]

Considine R.V., Sinha M.K., Heiman M.L., Et al., Serum immunoreactive-leptin concentrations in normal-weight and obese humans, N. Engl. J. Med., 334, pp. 292-295, (1996)

[8]

Rahmouni K., Correia M.L., Haynes W.G., Mark A.L., Obesity-associated hypertension: New insights into mechanisms, Hypertension, 45, pp. 9-14, (2005)

[9]

Tartaglia L.A., The leptin receptor, J. Biol. Chem., 272, pp. 6093-6096, (1997)

[10]

Chua Jr. S.C., Chung W.K., Wu-Peng X.S., Et al., Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor, Science, 271, pp. 994-996, (1996)

← 1 2 3 4 5 →